Piven, P.A. today announced that a securities class action was commenced on behalf of shareholders who purchased, …
The European Commission (EC) has granted a marketing authorization for SPINRAZA (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA), Biogen (NASDAQ: BIIB) announced today.1 5q SMA is the most common form of the …
stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of …
But, "compared to peers, we regard Amgen as a more defensive stock, but also …
Louise and Nina Gunderson are a powerhouse mother/daughter financial advisory team with UBS Financial Services UBS in New York and we got to talk with them …
Oct. 07, 2015 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a …
Biogen Idec (NASDAQ: BIIB) reported Q3 EPS of $3.80, $0.31 better than the analyst estimate of $3.49. Revenue for the quarter came in at $2.5 billion versus the consensus estimate of $2.48 billion. “The third quarter was a period of …
Biogen’s stock took a big hit, and it had to temporarily yank the drug from the market. “It’s a company that hung by the thread of a thread so many times we all …
Nov 2 (Reuters) - Biogen Inc ::Biogen presents new data from long-term extension of phase 1b study of investigational alzheimer’s disease treatment aducanumab.Biogen Inc - ‍as of October 2017, Biogen and Eisai entered into a global …
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets …